This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Borden EC , Kim K , Ryan L , Blum RH , Shiraki M , Tormey DC , Comis RL , Hahn RG , Parkinson DR
Phase-Ii Trials of Interferon-Alpha and Interferon-Beta in Advanced Sarcomas
Journal of Interferon Research. 1992 Dec;12(6) :455-458
AbstractInterferons (IFNs)-alpha and -beta were administered to patients with metastatic sarcomas in two different Eastern Cooperative Oncology Group studies. In one study, patients received IFN-alpha2b, 20 million units/m2 i.v. 5 days/week x 4, then 10 million units s.c. t.i.w. In the second study, patients received IFN-beta(ser) 180 million units t.i.w. Of 87 patients evaluable for response, there were three responses in 64 patients (5%) treated with IFN-alpha-2b and no responses in 23 patients treated with IFN-beta(ser). Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha2b and 17% of patients receiving IFN-beta(ser). Further investigation of IFNs in sarcomas should depend on evidence from preclinical studies demonstrating synergistic effects of IFNs combined with a cytoreductive modality which has proven activity in these malignancies.
NotesEnglish Article KC716 J INTERFERON RES